GlyTherix is pleased to announce that Dr Nat Lenzo has been appointed to the board of the company. We welcome Dr Lenzo who not only has been a pioneer of targeted radiotherapy but is also an experienced founder of start-up biotech companies.

His skillset will complement the board and his combined clinical and commercial viewpoint will bring huge value at a time when the company is taking its technology back into the clinic for a key trial!